Alcaftadine, a new antihistamine with combined antagonist activity at histamine H1, H2, and H4 receptors

Journal of Receptor, Ligand and Channel Research

Volumn 5, Issue , 2012, Pages 9-20

  Gallois Bernos, Annabelle C ^a   Thurmond, Robin L ^b  

^a JOHNSON AND JOHNSON   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Allergic conjunctivitis; Antihistamine; Ketotifen; Ocular; Pheniramine

Indexed keywords

ALCAFTADINE; DEXAMETHASONE; HISTAMINE H1 RECEPTOR; HISTAMINE H4 RECEPTOR; KETOTIFEN;

ALLERGIC CONJUNCTIVITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHISTAMINE ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; FEMALE; GUINEA PIG; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN;

CAVIA;

EID: 84871633754     PISSN: None     EISSN: 1178699X     Source Type: Journal    
DOI: 10.2147/JRLCR.S39369     Document Type: Article

References (34)

1. Jutel M, Akdis M, Akdis CA. Histamine, histamine receptors and their role in immune pathology. Clin Exp Allergy. 2009;39(12):1786-1800.
2. Huang J-F, Thurmond R. The new biology of histamine receptors. Curr Allergy Asthma Rep. 2008;8(1):21-27.
3. Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol. 2005; 115(1):118-122.
4. Leonardi A. Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005;10(3):505-520.
5. Leonardi A, De Dominicis C, Motterle L. Immunopathogenesis of ocular allergy: a schematic approach to different clinical entities. Curr Opin Allergy Clin Immunol. 2007;7(5):429-435.
6. Abramowicz M, editor. Drugs for allergic disorders. Medical Letter Treatment Guidelines. 2010;8:9-18.
7. Greiner JV, Edwards-Swanson K, Ingerman A. Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15minutes and 16hours after instillation versus placebo and olopatadine 0.1%. Clin Ophthalmol. 2011;5:87-93.
8. Torkildsen G, Shedden A. The safety and efficacy of alcaftadine 0.25% ophthalmic solution for the prevention of itching associated with allergic conjunctivitis. Curr Med Res Opin. 2011;27(3):623-631.
9. Bohets H, McGowan C, Mannens G, Schroeder N, Edwards-Swanson K, Shapiro A. Clinical pharmacology of alcaftadine, a novel antihistamine for the prevention of allergic conjunctivitis. J Ocul Pharmacol Ther. 2011;27(2):187-195.
10. Janssens F, Diels G, Leenaerts J, inventors; Imidaz[2,1-b]benzazepine derivatives, compositions and method of use, 1995. United States Patent US5468743.
11. Awouters F, Vermeire J, Smeyers F, Vermote P, Van Beck R, Niemegeers CJE. Oral antiallergic activity in Ascaris hypersensitive dogs: a study of known antihistamines and of the new compounds ramastine (R 57 959) and levocabastine (R 50 547). Drug Dev Res. 1986;8(1-4):95-102.
12. Tagari P, Black C, Marshall S, Ford-Hutchinson AW. A rapid biochemical method for measuring antigen-induced pulmonary eosinophil margination in allergic guinea pigs. J Immunol Methods. 1993;163(1):49-58.
13. Smit MJ, Timmerman H, Hijzelendoorn JC, Fukui H, Leurs R. Regulation of the human histamine H1 receptor stably expressed in Chinese hamster ovary cells. Br J Pharmacol. 1996;117(6):1071-1080.
14. Leurs R, Smit MJ, Menge WM, Timmerman H. Pharmacological characterization of the human histamine H2 receptor stably expressed in Chinese hamster ovary cells. Br J Pharmacol. 1994;112(3):847-854.
15. Thurmond RL, Desai PJ, Dunford PJ, et al. A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties. J Pharmacol Exp Ther. 2004;309(1):404-413.
16. Cheng Y-C, Prusoff WH. Relation between the inhibition constant K1 and the concentration of inhibitor which causes fifty per cent inhibition (I50) of an enzymic reaction. Biochem Pharmacol. 1973;22(23):3099-3108.
17. Sharif NA, Xu SX, Miller ST, Gamache DA, Yanni JM. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases. J Pharmacol Exp Ther. 1996;278(3):1252-1261.
18. Cowden JM, Zhang M, Dunford PJ, Thurmond RL. The histamine H4 receptor mediates inflammation and pruritus in Th2-dependent dermal inflammation. J Invest Dermatol. 2010;130(4):1023-1033.
19. Dunford PJ, O'Donnell N, Riley JP, Williams KN, Karlsson L, Thurmond RL. The histamine H4 receptor mediates allergic airway inflammation by regulating the activation of CD4+ T cells. J Immunol. 2006;176(11):7062-7070.
20. Ling P, Ngo K, Nguyen S, et al. Histamine H4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule upregulation. Br J Pharmacol. 2004;142(1):161-171.
21. Simons FE, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol. 2011;128(6): 1139-1150.
22. Gelfand EW, Appajosyula S, Meeves S. Anti-inflammatory activity of H1-receptor antagonists: review of recent experimental research. Curr Med Res Opin. 2004;20(1):73-81.
23. Abelson MB, Udell IJ. H2-receptors in the human ocular surface. Arch Ophthalmol. 1981;99(2):302-304.
24. Woodward DF, Johnson L, Spada C, Chen J. Effect of cimetidine and pyrilamine on histamine-induced ocular surface hyperemia. J Ocul Pharmacol. 1986;2(3):275-278.
25. Nakano Y, Takahashi Y, Ono R, Kurata Y, Kagawa Y, Kamei C. Role of histamine H4 receptor in allergic conjunctivitis in mice. Eur J Pharmacol. 2009;608(1-3):71-75.
26. Zampeli E, Thurmond RL, Tiligada E. The histamine H4 receptor antagonist JNJ7777120induces increases in the histamine content of the rat conjunctiva. Inflamm Res. 2009;58(6):285-291.
27. Canonica GW, Ciprandi G. Antiallergic drugs and the immune response. Interactions and possible clinical relevance. Allergy. 1989;44(1):1-5.
28. Clark RAF, Sandler JA, Gallin JI, Kaplan AP. Histamine modulation of eosinophil migration. J Immunol. 1977;118(1):137-145.
29. Reher TM, Neumann D, Buschauer A, Seifert R. Incomplete activation of human eosinophils via the histamine H4-receptor: evidence for ligand-specific receptor conformations. Biochem Pharmacol. 2012;84(2):192-203.
30. Woodward DF, Spada CS, Hawley SB, Nieves AL. Conjunctival eosinophil infiltration evoked by histamine and immediate hypersensitivity. Modification by H1-and H2-receptor blockade. Invest Ophthalmol Vis Sci. 1986;27(10):1495-1503.
31. Leonardi A, Di Stefano A, Vicari C, Motterle L, Brun P. Histamine H4 receptors in normal conjunctiva and in vernal keratoconjunctivitis. Allergy. 2011;66(10):1360-1366.
32. Takahashi Y, Kagawa Y, Izawa K, Ono R, Akagi M, Kamei C. Effect of histamine H4 receptor antagonist on allergic rhinitis in mice. Int Immunopharmacol. 2009;9(6):734-738.
33. Ono SJ, Lane K. Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis. Drug Des Devel Ther. 2011;5:77-84.
34. Offiah I, Calder VL. Immune mechanisms in allergic eye diseases: what is new? Curr Opin Allergy Clin Immunol. 2009;9(5):477-481.